Australia's most trusted
source of pharma news
Tuesday, 17 February 2026
Posted 16 February 2026 PM
There's been a nice pay bump for Novartis CEO Vas Narasimhan whose compensation has soared by 30 per cent to reach AU$45 million (24.9 million Swiss francs) after the company exceeded its long-term financial targets.
The main driver of the pay rise was a handsome payout tied to Novartis' long-term performance plan with the company's flagship brands Entresto, Kisqali and Kesimpta achieving sales well above expectations.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.